Ignite Creation Date:
2024-05-06 @ 6:12 PM
Last Modification Date:
2024-10-26 @ 2:43 PM
Study NCT ID:
NCT05574881
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-02-26
First Post:
2022-10-05
Brief Title:
Dalpiciclib Fulvestrant Trastuzumab and Pertuzumab in HR Positive HER2 Positive Metastatic Breast Cancer
Sponsor:
Fudan University
Organization:
Fudan University
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-09-01
Start Date Type:
ACTUAL
Primary Completion Date:
2025-01-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2025-01-01
Completion Date Type:
ESTIMATED
First Submit Date:
2022-10-05
First Submit QC Date:
October 10 2022
Study First Post Date:
2022-10-12
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-02-23
Last Update Post Date:
2024-02-26
Last Update Post Date Type:
ACTUAL